Amoxicillin, clarithromycin, metronidazole, levoflooxacin, ppi Give each drug separate class , short moa, dose, adr, frequency

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have enough from the library plus my core pharmacology knowledge to give a complete, accurate answer. Here it is:

Drug Reference Table: Amoxicillin | Clarithromycin | Metronidazole | Levofloxacin | PPI


1. Amoxicillin

ParameterDetails
ClassAminopenicillin (Beta-lactam antibiotic)
MOAInhibits bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs), blocking peptidoglycan cross-linking → bactericidal
Dose500 mg TDS or 875 mg BD (oral); up to 80-90 mg/kg/day in children
Frequency3x/day (TDS) for 500 mg; 2x/day (BD) for 875 mg formulation
ADRsDiarrhea, nausea, skin rash, urticaria, anaphylaxis (rare), pseudomembranous colitis, maculopapular rash (esp. in EBV/mono)

2. Clarithromycin

ParameterDetails
ClassMacrolide antibiotic
MOABinds the 50S ribosomal subunit (23S rRNA, domain V) → inhibits peptide chain elongation and aminoacyl translocation → bacteriostatic (bactericidal at high doses)
Dose250-500 mg BD (oral); for H. pylori: 500 mg BD
FrequencyTwice daily (BD)
ADRsGI upset (nausea, abdominal pain, diarrhea), metallic taste, QT prolongation, hepatotoxicity (rare), CYP3A4 drug interactions (strong inhibitor)

3. Metronidazole

ParameterDetails
ClassNitroimidazole antibiotic / antiprotozoal
MOANitro group is reduced by anaerobic bacterial enzymes → forms reactive intermediates → causes DNA strand breakage and disrupts DNA replication → bactericidal against anaerobes and certain protozoa
Dose400-500 mg TDS (oral); 500 mg IV TDS for severe infections; H. pylori: 400-500 mg BD/TDS
Frequency3x/day (TDS) standard; BD for some regimens
ADRsMetallic/bitter taste, nausea, headache, peripheral neuropathy (prolonged use), disulfiram-like reaction with alcohol, CNS effects (seizures, encephalopathy - rare), dark/reddish-brown urine

4. Levofloxacin

ParameterDetails
ClassFluoroquinolone antibiotic (3rd generation)
MOAInhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA supercoiling/relaxation and strand separation → blocks DNA replication and transcription → bactericidal
Dose500-750 mg OD (oral or IV); H. pylori: 500 mg OD; CAP: 500 mg OD x 7-14 days; UTI: 250-500 mg OD
FrequencyOnce daily (OD)
ADRsNausea, diarrhea, headache, dizziness, QT prolongation, tendinopathy/tendon rupture (esp. Achilles, in elderly/steroid users), photosensitivity, peripheral neuropathy, seizures (rare), hypoglycemia/hyperglycemia in diabetics

5. PPI (Proton Pump Inhibitors) - e.g., Omeprazole, Pantoprazole, Rabeprazole

ParameterDetails
ClassProton pump inhibitor (antisecretory agent)
MOAIrreversibly inhibits H⁺/K⁺-ATPase (the proton pump) on the luminal surface of gastric parietal cells → blocks the final step of acid secretion → profound, long-lasting suppression of both basal and stimulated gastric acid
DoseOmeprazole/Pantoprazole: 20-40 mg OD; Rabeprazole: 20 mg OD; Esomeprazole: 20-40 mg OD
FrequencyOnce daily (OD), ideally 30-60 minutes before a meal (breakfast) for maximum efficacy
ADRsHeadache, diarrhea, nausea, abdominal pain; long-term: hypomagnesemia, vitamin B12 deficiency, C. difficile infection risk, bone fractures (osteoporosis risk), iron malabsorption, fundic gland polyps, rebound acid hypersecretion on abrupt withdrawal

Clinical note: These five drugs together are frequently used in H. pylori eradication regimens (e.g., clarithromycin triple therapy: PPI + amoxicillin + clarithromycin; or bismuth quadruple / levofloxacin-based rescue therapy). Metronidazole is used in penicillin-allergic patients as a substitute for amoxicillin.
Sources: Jawetz Medical Microbiology 28E | Goodman & Gilman's Pharmacological Basis of Therapeutics | Katzung Basic & Clinical Pharmacology 16E | Harrison's Principles of Internal Medicine 22E

Diagnostic test of peptic ulcer

Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching Images

peptic ulcer endoscopy diagnosis

This composite educational image features two frames (A and B) from an upper gastrointestinal endoscopy, illustrating the diagnosis and treatment of acute peptic ulcer bleeding in the duodenal bulb. Frame A demonstrates clinical findings of hematemesis and melena, showing two cratered, oozing ulcers located in the duodenum. Significant active hemorrhage is visible as bright red blood pooling over the mucosal surface. The largest ulcer measures approximately 10 mm in diameter with a visible base. Frame B shows the immediate post-intervention state following the administration of 1:10,000 epinephrine (4cc) and the deployment of metallic hemostatic clips. A hemostatic clip is clearly visible, mechanically compressing the ulcerated site to achieve primary hemostasis. The surrounding mucosa appears altered in color, showing a reddish-orange hue with reduced active bleeding compared to the initial diagnostic view. This sequence serves as a clinical teaching tool for endoscopic management of gastroduodenal artery-related bleeding and the utilization of endoscopic markers to guide subsequent angiographic interventions.

This composite educational image features two frames (A and B) from an upper gastrointestinal endoscopy, illustrating the diagnosis and treatment of acute peptic ulcer bleeding in the duodenal bulb. Frame A demonstrates clinical findings of hematemesis and melena, showing two cratered, oozing ulcers located in the duodenum. Significant active hemorrhage is visible as bright red blood pooling over the mucosal surface. The largest ulcer measures approximately 10 mm in diameter with a visible base. Frame B shows the immediate post-intervention state following the administration of 1:10,000 epinephrine (4cc) and the deployment of metallic hemostatic clips. A hemostatic clip is clearly visible, mechanically compressing the ulcerated site to achieve primary hemostasis. The surrounding mucosa appears altered in color, showing a reddish-orange hue with reduced active bleeding compared to the initial diagnostic view. This sequence serves as a clinical teaching tool for endoscopic management of gastroduodenal artery-related bleeding and the utilization of endoscopic markers to guide subsequent angiographic interventions.

This endoscopic clinical photograph from an upper gastrointestinal endoscopy (EGD) displays the lumen of the distal duodenal bulb. Centered in the frame is a single, approximately 1-cm ulcerated lesion. The ulcer is characterized by a clean base and a slightly protuberant, elevated morphology. Distinctive features include irregular, 'heaped-up' mucosal edges surrounding the ulcer crater, and a cluster of translucent air bubbles typical of the insufflation process. Clinically significant signs of hemorrhage are visible, specifically active oozing of bright red blood (Forrest classification 1B) from the ulcer's margin. The surrounding mucosa shows slight erythema and texture changes indicative of gastric heterotopia or secondary inflammation. This image is an educational example of a peptic ulcer with features suspicious for an underlying mass lesion, requiring differential diagnosis between benign peptic ulcer disease and malignant or stromal tumors such as a Gastrointestinal Stromal Tumor (GIST).

This endoscopic clinical photograph from an upper gastrointestinal endoscopy (EGD) displays the lumen of the distal duodenal bulb. Centered in the frame is a single, approximately 1-cm ulcerated lesion. The ulcer is characterized by a clean base and a slightly protuberant, elevated morphology. Distinctive features include irregular, 'heaped-up' mucosal edges surrounding the ulcer crater, and a cluster of translucent air bubbles typical of the insufflation process. Clinically significant signs of hemorrhage are visible, specifically active oozing of bright red blood (Forrest classification 1B) from the ulcer's margin. The surrounding mucosa shows slight erythema and texture changes indicative of gastric heterotopia or secondary inflammation. This image is an educational example of a peptic ulcer with features suspicious for an underlying mass lesion, requiring differential diagnosis between benign peptic ulcer disease and malignant or stromal tumors such as a Gastrointestinal Stromal Tumor (GIST).

This clinical photograph displays an upper gastrointestinal endoscopy (UGIE) view of the second part of the duodenum. The primary finding is a large, irregularly shaped ulcer approximately 2x2 cm in size, situated on the medial wall. The ulcer features prominent nodular margins and a base covered with dark, necrotic-appearing material and focal areas of hemorrhage. An arrow indicates the close anatomical proximity of the lesion to the duodenal papilla. The surrounding duodenal mucosa is erythematous and inflamed, with thickened, irregular folds and a granular texture suggestive of significant tissue reaction. This endoscopic view is critical for the differential diagnosis of duodenal pathologies, including malignancy (duodenal adenocarcinoma), complex peptic ulcer disease, or atypical presentations of granulomatous diseases like tuberculosis or groove pancreatitis. The image illustrates key markers for malignancy or chronic inflammation, such as nodularity and mucosal distortion.

This clinical photograph displays an upper gastrointestinal endoscopy (UGIE) view of the second part of the duodenum. The primary finding is a large, irregularly shaped ulcer approximately 2x2 cm in size, situated on the medial wall. The ulcer features prominent nodular margins and a base covered with dark, necrotic-appearing material and focal areas of hemorrhage. An arrow indicates the close anatomical proximity of the lesion to the duodenal papilla. The surrounding duodenal mucosa is erythematous and inflamed, with thickened, irregular folds and a granular texture suggestive of significant tissue reaction. This endoscopic view is critical for the differential diagnosis of duodenal pathologies, including malignancy (duodenal adenocarcinoma), complex peptic ulcer disease, or atypical presentations of granulomatous diseases like tuberculosis or groove pancreatitis. The image illustrates key markers for malignancy or chronic inflammation, such as nodularity and mucosal distortion.

Here is a complete, structured breakdown of the diagnostic tests for peptic ulcer disease (PUD):

Diagnostic Tests for Peptic Ulcer Disease


1. Endoscopy (OGD - Oesophago-Gastro-Duodenoscopy)

Gold Standard
  • What it does: Direct visual inspection of the gastric and duodenal mucosa; allows biopsy, H. pylori testing, and therapeutic intervention
  • Sensitivity/Specificity: High - most sensitive and specific test
  • Key advantages:
    • Visualizes ulcer size, location, depth, and bleeding stigmata
    • Biopsy from ulcer edge to exclude malignancy (mandatory for all gastric ulcers)
    • Allows biopsy-based H. pylori testing (rapid urease test, histology, culture)
    • Can be therapeutic (injection, clipping, cautery for bleeding ulcers)
  • Indications (mandatory):
    • Age >55 with new-onset dyspepsia
    • Any "alarm/red flag" symptoms (weight loss, dysphagia, hematemesis, melena, anemia, palpable mass)
    • Gastric ulcer - always biopsy to rule out cancer
    • Non-healing or recurrent ulcers
  • Limitation: Invasive, needs sedation; PPIs reduce sensitivity slightly
Endoscopic image of peptic ulcer (duodenal):
Endoscopic view of a duodenal bulb ulcer with active oozing (Forrest 1B) - classic peptic ulcer appearance on upper GI endoscopy

2. Tests for H. pylori (the primary cause of PUD)

H. pylori is found in ~70-90% of duodenal ulcers and ~60-70% of gastric ulcers, so its detection is central to PUD workup.

A. Non-Invasive Tests

TestPrincipleSensitivitySpecificityNotes
Urea Breath Test (UBT)Patient ingests C-13 or C-14 labelled urea; H. pylori urease splits it → labelled CO₂ detected in exhaled breath~95%~96%Best non-invasive test; used for diagnosis AND post-eradication confirmation; stop PPIs 2 weeks before
Stool Antigen Test (SAT)Detects H. pylori antigens in stool using monoclonal antibodies~94%~97%Good for diagnosis and confirmation of eradication; monoclonal > polyclonal
Serology (IgG antibody)Detects serum IgG against H. pylori~85%~79%Cannot distinguish active vs. past infection; cannot confirm eradication; cheap but least specific

B. Invasive Tests (Require Endoscopy + Biopsy)

TestPrincipleSensitivitySpecificityNotes
Rapid Urease Test (CLO test)Biopsy placed in urea + pH indicator; urease from H. pylori changes colour~90-95%~95-100%Quick result (1-24 hrs); first-line biopsy-based test
HistologyMicroscopic examination of biopsy with special stains (Giemsa, Warthin-Starry)~93-99%~95-99%Gold standard for H. pylori detection; also shows gastritis/dysplasia
CultureGrows H. pylori from biopsy~70-80%~100%Allows antibiotic sensitivity testing; slow (5-7 days); used when resistance suspected
PCRDetects H. pylori DNA in biopsy~>95%~>95%Detects resistance genes; research/specialist use

3. Barium Meal / Upper GI Series

  • What it shows: Barium fills ulcer crater → "niche" sign on X-ray; Hampton's line (radiolucent line across base of gastric ulcer); mucosal folds radiating toward crater
  • Use: When endoscopy is not available or patient cannot tolerate it
  • Sensitivity: Lower than endoscopy (~80% for gastric ulcer, 70% for duodenal)
  • Limitation: Cannot biopsy, cannot detect H. pylori; less sensitive for small ulcers; cannot differentiate benign from malignant

4. CT Scan / CT Enterography

  • Not a primary test for PUD
  • Useful for detecting complications - perforation (free air under diaphragm/peritoneum), penetration, gastric outlet obstruction
  • Can incidentally show gastric/duodenal thickening but sensitivity for ulcer is low

5. Serum Gastrin Level (for Zollinger-Ellison Syndrome)

  • Indicated when: multiple/refractory ulcers, ulcers in unusual locations (distal duodenum/jejunum), recurrent ulcers post-H. pylori eradication, diarrhea + PUD
  • Fasting serum gastrin >1000 ng/L + basal acid output >15 mmol/hr → diagnostic of gastrinoma (ZES)
  • Secretin stimulation test: Secretin IV → paradoxical rise in gastrin >120 pg/mL in ZES (normally gastrin falls)

6. Gastric Acid Analysis (Basal Acid Output / BAO)

  • Measures acid secretion via nasogastric tube aspiration
  • BAO >15 mEq/hr suggests ZES
  • Rarely used in routine PUD; mainly for suspected hypersecretory states

Summary: When to Use Which Test

Clinical SituationPreferred Test
Standard PUD workup, age <55, no alarm featuresTest and treat: Urea Breath Test or Stool Antigen Test
Age >55, alarm symptoms, or gastric ulcerEndoscopy + biopsy (CLO test + histology)
Post-eradication confirmation (4-6 weeks after treatment)UBT or SAT (not serology)
Suspected perforation/complicationCT scan / AXR
Recurrent/refractory ulcers - exclude ZESFasting serum gastrin + secretin stimulation test
Suspected antibiotic resistanceCulture + sensitivity

Key points from Yamada's Textbook of Gastroenterology: "Endoscopy is the test of choice. In the past, barium contrast studies were routinely used... CT scans are much less sensitive and are not the test of choice. For gastric ulcer, supplementary biopsy is still recommended to increase diagnostic specificity and rule out malignancy."
Sources: Yamada's Textbook of Gastroenterology 7E | Harrison's Principles of Internal Medicine 22E | Sleisenger & Fordtran's GI and Liver Disease
This is a shared conversation. Sign in to Orris to start your own chat.